Roy E Strowd1, Katrina Swett1, Michele Harmon1, Annette F Carter1, Aurora Pop-Vicas1, Michael Chan1, Stephen B Tatter1, Thomas Ellis1, Maria Blevins1, Kevin High1, Glenn J Lesser1. 1. Department of Neurology, Wake Forest School of Medicine, Winston-Salem, North Carolina (R.E.S.); Department of Biostatistics, Wake Forest School of Public Health, Wake Forest University Health Sciences, Winston-Salem, North Carolina (K.S.); Department of Internal Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina (M.H., A.F.C., G.J.L.); Division of Infectious Disease, Alpert Medical School at Brown University, Providence, Rhode Island (A.P.); Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina (M.C.); Department of Neurosurgery, Wake Forest School of Medicine, Winston-Salem, North Carolina (S.B.T.); Department of Internal Medicine, Section on Infectious Disease, Wake Forest School of Medicine, Winston-Salem, North Carolina (M.B., K.H.).
Abstract
BACKGROUND: Patients with central nervous system (CNS) malignancies represent an "at-risk" population for contracting influenza, particularly if they are receiving ongoing chemotherapy, radiation, and/or glucocorticoid treatment. The Centers for Disease Control endorses vaccination for these patients, although data are not available to indicate whether they mount an immunologic response adequate to achieve clinical protection. METHODS: A pilot prospective cohort study was designed to evaluate the immunogenicity of the standard-dose trivalent inactivated influenza vaccine in patients with malignant CNS tumors. Baseline data collection included diagnosis, chemotherapy, timing of chemotherapy or radiation relative to vaccination, and glucocorticoid dose. Serum samples were collected at baseline, day 14, day 28, and month 3 following vaccination. Samples were tested using hemagglutinin inhibition to determine seroconversion (4-fold rise in titer) and seroprotection (titer >1:40). RESULTS: A total of 38 patients were enrolled (mean age, 54 years ±13.5 years, 60.5% male, 94.7% Caucasian, and 5.3% African American). CNS tumor diagnoses included glioblastoma multiforme (55.2%), other high-grade glioma (13.2%), low-grade glioma (15.8%), and primary CNS lymphoma (15.8%). At enrollment, 20 patients (52.6%) were taking glucocorticoids, 25 (65.8%) were on active chemotherapy, and 3 (7.9%) were undergoing radiation. Seroconversion rates at day 28 for the A/H1N1, A/H3N2, and B strains were 37%, 23% and 23%, respectively. Seroprotection was 80%, 69%, and 74%, respectively. All rates were significantly lower than published rates in healthy adults (P < .001). CONCLUSION: Influenza vaccine immunogenicity is significantly reduced in patients with CNS malignancies. Future studies are needed to determine the causative etiologies and appropriate vaccination strategies.
BACKGROUND:Patients with central nervous system (CNS) malignancies represent an "at-risk" population for contracting influenza, particularly if they are receiving ongoing chemotherapy, radiation, and/or glucocorticoid treatment. The Centers for Disease Control endorses vaccination for these patients, although data are not available to indicate whether they mount an immunologic response adequate to achieve clinical protection. METHODS: A pilot prospective cohort study was designed to evaluate the immunogenicity of the standard-dose trivalent inactivated influenza vaccine in patients with malignant CNS tumors. Baseline data collection included diagnosis, chemotherapy, timing of chemotherapy or radiation relative to vaccination, and glucocorticoid dose. Serum samples were collected at baseline, day 14, day 28, and month 3 following vaccination. Samples were tested using hemagglutinin inhibition to determine seroconversion (4-fold rise in titer) and seroprotection (titer >1:40). RESULTS: A total of 38 patients were enrolled (mean age, 54 years ±13.5 years, 60.5% male, 94.7% Caucasian, and 5.3% African American). CNS tumor diagnoses included glioblastoma multiforme (55.2%), other high-grade glioma (13.2%), low-grade glioma (15.8%), and primary CNS lymphoma (15.8%). At enrollment, 20 patients (52.6%) were taking glucocorticoids, 25 (65.8%) were on active chemotherapy, and 3 (7.9%) were undergoing radiation. Seroconversion rates at day 28 for the A/H1N1, A/H3N2, and B strains were 37%, 23% and 23%, respectively. Seroprotection was 80%, 69%, and 74%, respectively. All rates were significantly lower than published rates in healthy adults (P < .001). CONCLUSION: Influenza vaccine immunogenicity is significantly reduced in patients with CNS malignancies. Future studies are needed to determine the causative etiologies and appropriate vaccination strategies.
Authors: Stuart A Grossman; Xiaobu Ye; Glenn Lesser; Andrew Sloan; Hetty Carraway; Serena Desideri; Steven Piantadosi Journal: Clin Cancer Res Date: 2011-07-07 Impact factor: 12.531
Authors: A Kempe; C B Hall; N E MacDonald; H R Foye; K A Woodin; H J Cohen; E D Lewis; M Gullace; C L Gala; C S Dulberg; E Katsanis Journal: J Pediatr Date: 1989-07 Impact factor: 4.406
Authors: Leah J McGrath; Abhijit V Kshirsagar; Stephen R Cole; Lily Wang; David J Weber; Til Stürmer; M Alan Brookhart Journal: Arch Intern Med Date: 2012-04-09
Authors: Andreas F Hottinger; Anne-Claude C George; Michael Bel; Laurence Favet; Christophe Combescure; Sara Meier; Stéphane Grillet; Klara Posfay-Barbe; Laurent Kaiser; Claire-Anne Siegrist; Pierre-Yves Dietrich Journal: Oncologist Date: 2012-02-21
Authors: Lisa A Jackson; Manjusha J Gaglani; Harry L Keyserling; John Balser; Nancy Bouveret; Louis Fries; John J Treanor Journal: BMC Infect Dis Date: 2010-03-17 Impact factor: 3.090
Authors: Roy E Strowd; Gregory Russell; Fang-Chi Hsu; Annette F Carter; Michael Chan; Stephen B Tatter; Adrian W Laxton; Martha A Alexander-Miller; Kevin High; Glenn J Lesser Journal: Neurooncol Pract Date: 2018-01-06